NCT06482099View on ClinicalTrials.gov

SPECIAL INVESTIGATION FOR ABRYSVO IN PREGNANT WOMEN AND INFANTS

Active, not recruitingOBSERVATIONAL

Enrollment

490

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

March 11, 2026

Study Completion Date

March 11, 2026

Conditions

Respiratory Tract Infection

Interventions

BIOLOGICAL

RSVpreF vaccine

Injection in the muscle, 1 dose 0.5mL

Trial Locations (1)

10001

Pfizer, New York

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY